查找临床试验
已按「遗传性视网膜病变」检索，对应国际通用词 inherited retinal disease
共找到 104 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 00:25，每 5 分钟自动同步正在招募不适用NCT07502664
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
United States
年龄 18 Years – 不限
Ray Therapeutics, Inc.
正在招募不适用NCT01793168
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
United States
年龄 不限 – 不限
Sanford Health
正在招募I 期 / II 期NCT07439887
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
United States
年龄 16 Years – 不限
Ray Therapeutics, Inc.
正在招募I 期NCT07734064
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
United States
年龄 6 Years – 不限
Astellas Institute for Regenerative Medicine
正在招募不适用NCT06315556
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
United Kingdom
年龄 不限 – 1 Year
Bayer
正在招募不适用NCT03233646
Retinal Imaging in Neurodegenerative Disease
United States
年龄 18 Years – 不限
Duke University
正在招募II 期NCT04040205
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
United States
年龄 18 Years – 不限
Medical College of Wisconsin
正在招募I 期 / II 期NCT06591793
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
Italy、United Kingdom
年龄 18 Years – 50 Years
AAVantgarde Bio Srl
正在招募III 期NCT07419334
Study of ALK-001 on the Progression of Stargardt Disease
United States
年龄 8 Years – 45 Years
Alkeus Pharmaceuticals, Inc.
正在招募I 期 / II 期NCT06891885
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
United States
年龄 18 Years – 不限
Sumitomo Pharma America, Inc.
正在招募I 期NCT07836452
A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
Australia
年龄 12 Years – 45 Years
City Therapeutics
正在招募I 期NCT06291935
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
Germany
年龄 18 Years – 不限
VeonGen Therapeutics GmbH